Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

Bristol Myers Squibb raises 2025 revenue and EPS guidance on Q3 earnings beat, driven by strong Eliquis and Opdivo sales.

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY ...

Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer ...

Opdivo revenue grew 7% to $2.5 billion in Q3 on continued demand. ・The company now expects high single-digit to low ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump ...